T-X (Synthetics 2010+)

*Previous Articles 2000-2009 List

SYNTHETICS and COMPOUNDS THAT AFFECT the ENDOCANNABINOID SYSTEM 2010-2016

TAK- 875 / FASIGLIFAM (GPR40 Agonist)
TAK-937 (CB1 and CB2 Agonist)
TARANABANT / MK-0364* (CB1 Inverse Agonist, Weight Loss Drug)
TM-38837 (Mostly Peripherally Restricted CB1 Antagonist)
UR-144 (CB1 Antagonist)
URB-447 (CB1 Antagonist)
URB-584 (Inhibits FAAH, Slowing Cannabinoid Destruction)
URB-597 / KDS-4103* (Slows Cannabinoid Destruction in the Body, Not the Brain)
URB-602* (Stops Breakdown of Anandamide and 2-AG)
URB-754* (Slows Cannabinoid Destruction)
URB-937* (Slows Cannabinoid Destruction)
VD-60 (Peripheral Cannabinoid Receptor 1 Antagonist)
WIN 55,212-2* (CB1 and CB2 Agonist)
WWL-70* (Prevents Breakdown of 2-AG)
XLR-11 (Potent CB1 and CB2 Agonist)
top


TAK-875 / FASIGLIFAM
TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats (full–2011) http://jpet.aspetjournals.org/content/339/1/228.long
Takeda moves potential first-in-class diabetes drug into phase III (news–2011) http://www.pharmafile.com/news/166980/takeda-diabetes-tak-875-phase-iii
A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects With Type 2 Diabetes (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22669289
Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22490067
TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22374408
Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920793/
A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1 (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794927/
Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600727/
Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554318/
TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23848179
Fasiglifam as a new potential treatment option for patients with type 2 diabetes (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24195772
High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875 (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25043059
Optimization of GPR40 Agonists for Type 2 Diabetes (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24900872
Physiology and therapeutics of the free fatty acid receptor GPR40 (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24373235
G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24234912
Docosahexaenoic acid, G protein-coupled receptors, and melanoma: is G protein-coupled receptor 40 a potential therapeutic target? (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24576779


TAK-937
Contribution of Hypothermia and CB(1) Receptor Activation to Protective Effects of TAK-937, a Cannabinoid Receptor Agonist, in Rat Transient MCAO Model (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397930/?tool=pubmed
Cerebroprotective effects of TAK-937, a cannabinoid receptor agonist, on ischemic brain damage in middle cerebral artery occluded rats and non-human primates (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22119394
Cerebroprotective effects of TAK-937, a novel cannabinoid receptor agonist, in permanent and thrombotic focal cerebral ischemia in rats: Therapeutic time window, combination with t-PA and efficacy in aged rats (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23791950


TARANABANT / MK-0364
Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2976981/
Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant (full–2010) http://onlinelibrary.wiley.com/doi/10.1111/j.1471-4159.2009.06549.x/full
A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes (full–2010) http://onlinelibrary.wiley.com/doi/10.1111/j.1463-1326.2009.01188.x/full
A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study (abst–2010) http://www.nature.com/ijo/journal/v34/n5/abs/ijo201021a.html
Randomized, controlled, double-blind trial of taranabant for smoking cessation (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20191360
Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans (abst – 2010) http://www.ncbi.nlm.nih.gov/pubmed/20722472
Neuropsychiatric adverse effects of centrally acting antiobesity drugs (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21951371
Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22722508
The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23692073
Development of amorphous solid dispersion formulations of a poorly water-soluble drug, MK-0364 (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23651642


TM-38837
Experimental obesity drug avoids brain effects that troubled predecessors (news–2010) http://phys.org/news197905295.html
Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: A PET study (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24293119
Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23601084


UR-144
URB-754: A new class of designer drug and 12 synthetic cannabinoids detected in illegal products (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/23063179
Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23042760
Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23916483
Analysis of UR-144 and its pyrolysis product in blood and their metabolites in urine (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24314536
First Metabolic Profile of XLR-11, a Novel Synthetic Cannabinoid, Obtained by Using Human Hepatocytes and High-Resolution Mass Spectrometry (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24014837
Toxicological Findings of Synthetic Cannabinoids in Recreational Users (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23970540
Identification of Novel Third-Generation Synthetic Cannabinoids in Products by Ultra-Performance Liquid Chromatography and Time-of-Flight Mass Spectrometry (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23946450
UR-144 in products sold via the Internet: Identification of related compounds and characterization of pyrolysis products (abst–2013)http://onlinelibrary.wiley.com/doi/10.1002/dta.1456/abstract
Identification and quantification of synthetic cannabinoids in ‘spice-like’ herbal mixtures: A snapshot of the German situation in the autumn of 2012 (full – 2014) http://onlinelibrary.wiley.com/doi/10.1002/dta.1499/full
LC-QTOF-MS as a superior strategy to immunoassay for the comprehensive analysis of synthetic cannabinoids in urine (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24424965
Driving under the influence of synthetic cannabinoids (“Spice”): a case series (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/23636569
Quantitative Measurement of XLR11 and UR-144 in Oral Fluid by LC-MS-MS (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24812645
Enzyme-Linked Immunosorbent Assay (ELISA) for the Detection of Use of the Synthetic Cannabinoid Agonists UR-144 and XLR-11 in Human Urine (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24908262


URB-447
Endocannabinoid signaling in the gut mediates preference for dietary unsaturated fats (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659363/


URB-584
Hemopressin, an inverse agonist of cannabinoid receptors, inhibits neuropathic pain in rats (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24703998


URB-597 / KDS-4103
Behavioral sequelae following acute diisopropylfluorophosphate intoxication in rats: comparative effects of atropine and cannabinomimetics (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2854260/?tool=pubmed
Preservation of Striatal Cannabinoid CB1 Receptor Function Correlates with the Antianxiety Effects of Fatty Acid Amide Hydrolase Inhibition (full–2010) http://molpharm.aspetjournals.org/content/78/2/260.long
Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260554/?tool=pubmed
Regulation of nausea and vomiting by cannabinoids (full–2010) http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2010.01176.x/pdf
Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis (abst–2010) http://www.unboundmedicine.com/medline/ebm/record/21185649/abstract/Local_application_of_the_endocannabinoid_hydrolysis_inhibitor_URB597_reduces_nociception_in_spontaneous_and_chemically_induced_models_of_osteoarthritis_
Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington’s disease transgenic mice (abst–2010) http://www.unboundmedicine.com/medline/ebm/record/20600638/abstract/Behavioural_and_molecular_consequences_of_chronic_cannabinoid_treatment_in_Huntington%27s_disease_transgenic_mice_
Potential First-in-Class Compound, Reveals New Approach to the Treatment of Pain (D3) (news–2010) http://www.drugs.com/clinical_trials/potential-first-class-compound-reveals-new-approach-pain-d3-10133.html
A new drug that kills pain like marijuana, without getting you stoned (news–2010) http://io9.com/5643337/a-new-drug-that-kills-pain-like-marijuana-without-getting-you-stoned
Pain target enzyme’s working made crystal clear (news–2010) http://www.rsc.org/chemistryworld/News/2010/May/26051001.asp
Endocannabinoid regulation of acute and protracted nicotine withdrawal: effect of FAAH inhibition (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227620/?tool=pubmed
Increasing Antiproliferative Properties of Endocannabinoids in N1E-115 Neuroblastoma Cells through Inhibition of Their Metabolism (full – 2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3203169/?tool=pubmed
Administration of URB597, oleoylethanolamide or palmitoylethanolamide increases waking and dopamine in rats (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3136458/?tool=pubmed
Pharmacological elevation of anandamide impairs short-term memory by altering the neurophysiology in the hippocampus (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156972/
Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21740924
L-Type Calcium Channel Mediates Anticonvulsant Effect of Cannabinoids in Acute and Chronic Murine Models of Seizure (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21928146
Role of endocannabinoid and glutamatergic systems in DOI-induced head-twitch response in mice (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21504759
A role for the ventral hippocampal endocannabinoid system in fear-conditioned analgesia and fear responding in the presence of nociceptive tone in rats (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21864979
The endocannabinoid, anandamide, augments Notch-1 signaling in cultured cortical neurons exposed to amyloid-beta and in the cortex of aged rats (full–2012) http://www.jbc.org/content/early/2012/08/13/jbc.M112.350678.long
The FAAH inhibitor URB597 efficiently reduces tyrosine hydroxylase expression through CB1 and FAAH-independent mechanisms (full–2012) http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2012.02208.x/full
Medial prefrontal cortex endocannabinoid system modulates baroreflex activity through CB1 receptors (full–2012) http://ajpregu.physiology.org/content/302/7/R876
The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation (full–2012) http://www.jneuroinflammation.com/content/9/1/79
The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action (full–2012) http://www.biomedcentral.com/1471-2407/12/92
Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525790/
The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation (full–2012) http://www.jneuroinflammation.com/content/9/1/79
The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423256/
Pharmacological modulation of the endocannabinoid signalling alters binge-type eating behaviour in female rats (full–2012) http://onlinelibrary.wiley.com/doi/10.1111/bph.12014/full
Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366638/
Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3449266/
Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid / endovanilloid system (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481534/
Vascular metabolism of anandamide to arachidonic acid affects myogenic constriction in response to intraluminal pressure elevation (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22285599
Inhibition of fatty acid amide hydrolase by URB597 attenuates the anxiolytic-like effect of acetaminophen in the mouse elevated plus-maze test (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22750843
Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/21952131
Endothelium-dependent mechanisms of the vasodilatory effect of the endocannabinoid, anandamide, in the rat pulmonary artery (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22627170
Potential Pain Medication Targets Peripheral Nerves (news–2012) http://www.drugabuse.gov/news-events/nida-notes/potential-pain-medication-targets-peripheral-nerves
Modulating the endocannabinoid system in human health and disease: successes and failures (full–2013) http://onlinelibrary.wiley.com/doi/10.1111/febs.12260/pdf
Monounsaturated fatty acids generated via stearoyl CoA desaturase-1 are endogenous inhibitors of fatty acid amide hydrolase (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839776/
Full Inhibition of Spinal FAAH Leads to TRPV1-Mediated Analgesic Effects in Neuropathic Rats and Possible Lipoxygenase-Mediated Remodeling of Anandamide Metabolism (full–2013) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0060040 social withdrawal results from deficient stimulation of cannabinoid CB1 receptors: implications for schizophrenia (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717536/
Endocannabinoid anandamide mediates hypoxic pulmonary vasoconstriction (full–2013) http://www.pnas.org/content/110/46/18710.full?sid=b685d344-5523-4371-a682-b03610d573e6
Inhibition of FAAH and activation of PPAR: New approaches to the treatment of cognitive dysfunction and drug addiction (full – 2013)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662489/
A role for the endocannabinoid system in exercise-induced spatial memory enhancement in mice (full – 2013)http://www.ncbi.nlm.nih.gov/pubmed/24115292
Targeting the Endocannabinoid System to Treat Sepsis (review – 2013) http://www.signavitae.com/articles/review-articles/222-targeting-the-endocannabinoid-system-to-treat-sepsis
Modulation by 17β-estradiol of anandamide vasorelaxation in normotensive and hypertensive rats: a role for TRPV1 but not fatty acid amide hydrolase (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23340220
Inhibition Of Fatty Acid Amide Hydrolase Activates Nrf2 Signaling And Induces Heme Oxygenase 1 Transcription In Breast Cancer Cells (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23347118
Inhibition of endocannabinoid degradation in experimental endotoxemia reduces leukocyte adhesion and improves capillary perfusion in the gut (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23382309
The complex effects of cannabinoids on insulin secretion from rat isolated islets of Langerhans (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/23499687
Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23625705
The fatty acid amide hydrolase inhibitor, URB597, promotes retinal ganglion cell neuroprotection in a rat model of optic nerve axotomy (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23643752
Emotional, endocrine and brain anandamide response to social challenge in infant male rats (abst – 2013)http://www.ncbi.nlm.nih.gov/pubmed/23660109
Effects of anandamide and other CB1 ligands on cognitive function (abst – 2013) http://www.fasebj.org/cgi/content/meeting_abstract/27/1_MeetingAbstracts/1097.10?sid=eea722c0-971c-4daa-8b8c-38c0c63c19ad
Effects of compounds that interfere with the endocannabinoid system on behaviors predictive of anxiolytic and panicolytic activity in the elevated T-maze (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23711591
The effects of anandamide signaling enhanced by the FAAH inhibitor URB597 on coping styles in rats (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23743650
Anandamide modulates the neuroendocrine responses induced by extracellular volume expansion (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23875874
Effects of the fatty acid amide hydrolase inhibitor URB597 on coping behavior under challenging conditions in mice (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24037493
Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB1 and CB2 receptors (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24148808
Endocannabinoids underlie reconsolidation of hedonic memories in Wistar rats (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24247477
Endocannabinoid Signaling in Hypothalamic-Pituitary-Adrenocortical Axis Recovery Following Stress: Effects of Indirect Agonists and Comparison of Male and Female Mice (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24316201
Long-term consequences of perinatal fatty acid amino hydrolase inhibition (abst–2013) http://onlinelibrary.wiley.com/doi/10.1111/bph.12500/abstract
Antidepressants and Changes in Concentration of Endocannabinoids and N-Acylethanolamines in Rat Brain Structures (full–2014) http://download.springer.com/static/pdf/559/art%253A10.1007%252Fs12640-014-9465-0.pdf?auth66=1395868546_998a8d5d87cb02529572689ff9213e4a&ext=.pdf
Mechanisms of endothelium-dependent relaxation evoked by anandamide in isolated human pulmonary arteries (full–2014) http://download.springer.com/static/pdf/387/art%253A10.1007%252Fs00210-014-0961-9.pdf?auth66=1396559334_2a7771f3b0767a5092c7c4a570374992&ext=.pdf
Elevation of Endogenous Anandamide Impairs LTP, Learning and Memory through CB1 Receptor Signaling in Mice (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24648181
Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24709540
Endocannabinoid contribution to Δ9-tetrahydrocannabinol discrimination in rodents (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24858366
Attenuation of serotonin-induced itch responses by inhibition of endocannabinoid degradative enzymes, fatty acid amide hydrolase and monoacylglycerol lipase (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24915981
Strain- and context-dependent effects of the anandamide hydrolysis inhibitor URB597 on social behavior in rats (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24933531
Endocannabinoid modulation by FAAH and MAGL within the analgesic circuitry of the periaqueductal grey (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25041240
The FAAH inhibitor PF-04457845 has THC-like rewarding and reinstatement effects in squirrel monkeys and increases dopamine levels in the nucleus accumbens shell in rats (abst–2014) http://www.fasebj.org/content/28/1_Supplement/838.6.abstract?sid=db987fd0-3ef0-4796-aff6-4103f0c84daf


URB-602
Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-γ (full–2011) http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2011.01444.x/full
Expression and function of monoacylglycerol lipase in mouse β-cells and human islets of Langerhans (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22739267
Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB1 and CB2 receptors (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24148808


URB-754
URB-754: A new class of designer drug and 12 synthetic cannabinoids detected in illegal products (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23063179


URB-937
Compound boosts marijuana-like chemical in the body to relieve pain at injury site (news-2010) http://www.eurekalert.org/pub_releases/2010-09/uoc–cbm092010.php
Research Reaps Reefer Madness (news–2010) http://www.newuniversity.org/2010/10/news/research-reaps-reefer-madness/
Pharmacological characterization of the peripheral FAAH inhibitor URB937 in female rodents: interaction with the Abcg2 transporter in the blood-placenta barrier (full–2012) http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2012.02098.x/full
Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525790/
Peripheral and Spinal Activation of Cannabinoid Receptors by Joint Mobilization Alleviates Postoperative Pain in Mice (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24120553
Inhibition of Peripheral Fatty Acid Amide Hydrolase Depresses Activities of Bladder Mechanosensitive Nerve Fibers of the Rat (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24746881


VD-60
The peripheral cannabinoid receptor 1 antagonist VD60 efficiently inhibits carbon tetrachloride-intoxicated hepatic fibrosis progression (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24459189


WIN 55,212-2
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 (full–2010) http://pharmrev.aspetjournals.org/content/62/4/588.full.pdf+html
Cannabinoid-mediated inhibition of recurrent excitatory circuitry in the dentate gyrus in a mouse model of temporal lobe epilepsy (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2871782/?tool=pubmed
Cannabinoids excite circadian clock neurons (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2927117/?tool=pubmed
A synthetic cannabinoid agonist promotes oligodendrogliogenesis during viral encephalitis in rats (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981070/?tool=pubmed
The synthetic cannabinoid WIN 55,212-2 sensitizes hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating p8/CCAAT/enhancer binding protein homologous protein (CHOP)/death receptor 5 (DR5) axis (full–2010) http://molpharm.aspetjournals.org/content/77/5/854.long
Antitumorigenic Effects of Cannabinoids beyond Apoptosis (full–2010) http://jpet.aspetjournals.org/content/332/2/336.full?sid=af53ea87-ab4b-426e-9c7e-8f750e9c4a17
Sex difference in cell proliferation in developing rat amygdala mediated by endocannabinoids has implications for social behavior (full–2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996668/?tool=pubmed
The Neuroprotective Effect of Cannabinoid Receptor Agonist (WIN55,212-2) in Paraoxon Induced Neurotoxicity in PC12 Cells and N-methyl-D-aspartate Receptor Interaction (full–2010) http://celljournal.org/library/upload/article/af_4334422Hashemi.pdf
Antiproliferative effects of cannabinoid agonists on deep infiltrating endometriosis (full-2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993285/
The Endocannabinoid System Tonically Regulates Inhibitory Transmission and Depresses the Effect of Ethanol in Central Amygdala (full – 2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904853/
Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs (full – 2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912042/pdf/zpt347.pdf
The cannabinoid WIN55212-2 promotes neural repair after neonatal hypoxia-ischemia (full – 2010) http://stroke.ahajournals.org/content/41/12/2956.long
Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis (full – 2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893662/
The effect of the activation of cannabinoid receptor on the proliferation and apoptosis of hepatoma HepG2 cells (abst – 2010) http://www.ncbi.nlm.nih.gov/pubmed/20368112
WIN55212-2 ameliorates atherosclerosis associated with suppression of pro-inflammatory responses in ApoE-knockout mice (abst – 2010) http://www.ncbi.nlm.nih.gov/pubmed/20868672
The cannabinoid receptor agonist WIN 55,212-2 inhibits antigen-induced plasma extravasation in guinea pig airways (abst–2010) http://www.ncbi.nlm.nih.gov/pubmed/20150748
Pharmacologically induced hypothermia with cannabinoid receptor agonist WIN55, 212-2 after cardiopulmonary resuscitation (abst–2010) http://journals.lww.com/ccmjournal/Abstract/2010/12000/Pharmacologically_induced_hypothermia_with.2.aspx
Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats (abst-2010) http://www.ncbi.nlm.nih.gov/pubmed/19854030
Effect of a synthetic cannabinoid agonist on the proliferation and invasion of gastric cancer cells (abst – 2010) http://www.ncbi.nlm.nih.gov/pubmed/20336665
Cannabinoid Receptor Agonist WIN-55,212-2 Protects Differentiated PC12 Cells From Organophosphorus- Induced Apoptosis (abst – 2010) http://ijt.sagepub.com/content/29/2/201.abstract
Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain (abst – 2010) http://www.ncbi.nlm.nih.gov/pubmed/20920894
WIN55,212-2 induces cytoplasmic vacuolation in apoptosis-resistant MCL cells (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223692/
Cannabinoid Agonists Inhibit Neuropathic Pain Induced by Brachial Plexus Avulsion in Mice by Affecting Glial Cells and MAP Kinases (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172222/?tool=pubmed
Regulatory effect of cannabinoid receptor agonist on chemokine-induced lymphocyte chemotaxis (full–2011) https://www.jstage.jst.go.jp/article/bpb/34/7/34_7_1090/_pdf
Cannabinoids prevent the development of behavioral and endocrine alterations in a rat model of intense stress (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242307/
Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimers’ disease (full – 2011) http://molpharm.aspetjournals.org/content/early/2011/02/24/mol.111.071290.long
A Pilot Study into the Effects of the CB1 Cannabinoid Receptor Agonist WIN55,212-2 or the Antagonist/Inverse Agonist AM251 on Sleep in Rats (full–2011)
http://www.hindawi.com/journals/sd/2011/178469/
Chronic Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids (full–2011)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3051379/pdf/bph0162-1060.pdf
Cannabinoid exposure during zebra finch sensorimotor vocal learning persistently alters expression of endocannabinoid signaling elements and acute agonist responsiveness (full–2011) http://www.biomedcentral.com/1471-2202/12/3
Identification of the synthetic cannabinoid R(+)WIN55,212-2 as a novel regulator of IFN regulatory factor 3 (IRF3) activation and IFN-{beta} expression: relevance to therapeutic effects in models of multiple sclerosis (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3060486/
Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent (full–2011) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280884/
Cannabidiol inhibits the hyperphagia induced by cannabinoid-1 or serotonin-1A receptor agonists (full–2011) http://www.sciencedirect.com/science/article/pii/S0091305711000128
The Cannabinoid WIN 55212-2 Mitigates Apoptosis and Mitochondrial Dysfunction After Hypoxia Ischemia (abst – 2011) http://www.ncbi.nlm.nih.gov/pubmed/21909954
Protective effects of CB1 receptor agonist WIN 55.212-2 in seizure activity in the model of temporal lobe epilepsy (abst–2011) http://www.unboundmedicine.com/medline/ebm/record/21469332/abstract/%5BProtective_effects_of_CB1_receptor_agonist_WIN_55_212_2_in_seizure_activity_in_the_model_of_temporal_lobe_epilepsy%5D_
Effects of repeated electroacupuncture on gene expression of cannabinoid receptor-1 and dopamine 1 receptor in nucleus accumbens-caudate nucleus region in inflammatory-pain rats (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21585053
Cannabinoid applications in glaucoma (abst – 2011) http://www.unboundmedicine.com/medline/ebm/record/21414525/abstract/Cannabinoid_applications_in_glaucoma_
Effect of ion pairing on in vitro transcorneal permeability of a Δ(9) -tetrahydrocannabinol prodrug: Potential in glaucoma therapy (abst–2011) http://www.unboundmedicine.com/medline/ebm/record/21989812/abstract/Effect_of_ion_pairing_on_in_vitro_transcorneal_permeability_of_a_%CE%94_9___tetrahydrocannabinol_prodrug:_Potential_in_glaucoma_therapy_
Win 55,212-2 reduces cardiac ischaemia-reperfusion injury in zucker diabetic fatty rats: role of cb2 receptors and cardiac inos/enos expression (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21309057
Antiproliferative mechanism of a cannabinoid agonist by cell cycle arrest in human gastric cancer cells (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21312237
Synthetic cannabinoid WIN 55,212-2 mesylate enhances the protective action of four classical antiepileptic drugs against maximal electroshock-induced seizures in mice (abst–2011) http://www.unboundmedicine.com/medline/ebm/record/21238473/abstract/Synthetic_cannabinoid_WIN_55212_2_mesylate_enhances_the_protective_action_of_four_classical_antiepileptic_drugs_against_maximal_electroshock_induced_seizures_in_mice_
The Effect of Hypoxia on G Protein Coupled (CB1) Receptor Gene Expression in Cortical B50 Neurons in Culture (abst–2011) http://www.maxwellsci.com/jp/abstract.php?jid=BJPT&no=92&abs=05
The cannabinoid WIN55, 212-2 abrogates dermal fibrosis in scleroderma bleomycin model (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21177293
The antimitogenic effect of the cannabinoid receptor agonist WIN55212-2 on human melanoma cells is mediated by the membrane lipid raft (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21807457
Effects of Cannabinoid Agonists on Sheep Sphincter of Oddi in vitro (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/21921665
Δ(9)-THC and WIN55,212-2 affect brain tissue levels of excitatory amino acids in a phenotype-, compound-, dose-, and region-specific manner (abst–2011) http://www.unboundmedicine.com/medline/ebm/record/21645556/abstract/%CE%94_9__THC_and_WIN55212_2_affect_brain_tissue_levels_of_excitatory_amino_acids_in_a_phenotype__compound__dose__and_region_specific_manner_
Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington’s disease (abst–2011) http://www.ncbi.nlm.nih.gov/pubmed/22207189
Dynamic changes to the endocannabinoid system in models of chronic pain (full–2012) http://rstb.royalsocietypublishing.org/content/367/1607/3300.full?sid=1569c370-cd5c-4358-89ff-857201f5e069
Reduced alcohol intake and reward associated with impaired endocannabinoid signaling in mice with a deletion of the glutamate transporter GLAST (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3372600/
The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation (full–2012) http://www.jneuroinflammation.com/content/9/1/79
Statistical parametric mapping reveals regional alterations in cannabinoid CB1 receptor distribution and G-protein activation in the 3D reconstructed epileptic rat brain (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3799958/
Prolonged oral Cannabinoid Administration prevents Neuroinflammation, lowers beta-amyloid Levels and improves Cognitive Performance in Tg APP 2576 Mice (full – 2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292807/
Synergistic interaction of pregabalin with the synthetic cannabinoid WIN 55,212-2 mesylate in the hot-plate test in mice: an isobolographic analysis (full – 2012) http://www.if-pan.krakow.pl/pjp/pdf/2012/3_723.pdf
Antiproliferative Effects of Cannabinoid Agonists on Deep Infiltrating Endometriosis (full – 2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993285/?tool=pubmed
Cannabinoids Facilitate the Swallowing Reflex Elicited by the Superior Laryngeal Nerve Stimulation in Rats (full – 2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507745/
The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α (full – 2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3408184/
Angiotensin II induces vascular endocannabinoid release, which attenuates its vasoconstrictor effect via CB1 cannabinoid receptors (full – 2012) http://www.jbc.org/content/early/2012/07/11/jbc.M112.346296.full.pdf+html
The periaqueductal gray contributes to bidirectional enhancement of antinociception between morphine and cannabinoids (full – 2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959123/
Cannabinoid receptor activation correlates with the pro-apoptotic action of the β2-adrenergic agonist, (R,R’)-4-methoxy-1-naphthylfenoterol, in HepG2 hepatocarcinoma cells (full–2012) http://jpet.aspetjournals.org/content/early/2012/07/09/jpet.112.195206.long
Cannabinoid receptor 1 suppresses transient receptor potential vanilloid 1-induced inflammatory responses to corneal injury (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3607947/
Neuron to Astrocyte Communication via Cannabinoid Receptors Is Necessary for Sustained Epileptiform Activity in Rat Hippocampus (full–2012) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0037320
Epileptiform activity in the CA1 region of the hippocampus becomes refractory to attenuation by cannabinoids in part because of endogenous γ-aminobutyric acid type B receptor activity (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3350599/
Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids (full-2012) http://rstb.royalsocietypublishing.org/content/367/1607/3254.full?sid=1569c370-cd5c-4358-89ff-857201f5e069
Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors (full – 2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481297/
Cannabinoids inhibit peptidoglycan-induced phosphorylation of NF-κB and cell growth in U87MG human malignant glioma cells (full – 2012) http://www.spandidos-publications.com/or/28/4/1176;jsessionid=52ED17697BFDC92E6F5F848306023474?text=fulltext
Review article: The endocannabinoid system in normal and pathological brain ageing (full–2012) http://rstb.royalsocietypublishing.org/content/367/1607/3326.full?sid=161e7b36-5055-448b-962e-697c782e901d
The cannabinoid agonist WIN55212-2 decreases l-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats (full – 2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273613/
Endocannabinoid modulation of jejunal afferent responses to LPS (full – 2012) http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2982.2012.01961.x/full
Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice (full – 2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389197/
The molecular connections between the cannabinoid system and endometriosis (full–2012) http://molehr.oxfordjournals.org/content/18/12/563.full
Tolerance to cannabinoid-induced behaviors in mice treated chronically with ethanol (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249519/
Neural Circuit in the Dorsal Raphe Nucleus Responsible for Cannabinoid-Mediated Increases in 5-HT Efflux in the Nucleus Accumbens of the Rat Brain (full–2012) http://www.hindawi.com/isrn/pharmacology/2012/276902/
Involvement of the Endocannabinoid System in Ethanol-Induced Corticostriatal Synaptic Depression (full–2012) https://www.jstage.jst.go.jp/article/jphs/120/1/120_12118FP/_pdf
Reduced infarct size and accumulation of microglia in rats treated with WIN 55,212-2 after neonatal stroke (full–2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446851/
Contrasting effects of different cannabinoid receptor ligands on mouse ingestive behavior (abst–2012) http://www.unboundmedicine.com/medline/ebm/record/22772336/abstract/Contrasting_effects_of_different_cannabinoid_receptor_ligands_on_mouse_ingestive_behaviour_
Inverse relationship of cannabimimetic (R+)WIN 55, 212 on behavior and seizure threshold during the juvenile period (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22019959
The Cannabinoid WIN 55212-2 Mitigates Apoptosis and Mitochondrial Dysfunction After Hypoxia Ischemia (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/21909954
Cannabinoids and muscular pain. Effectiveness of the local administration in rat (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22354705
Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB(1) receptor-mediated anti-inflammatory effects (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22342378
Cannabinoid 1 (CB1) receptor mediates WIN55, 212-2 induced hypothermia and improved survival in a rat post-cardiac arrest model (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22289684
Vascular metabolism of anandamide to arachidonic acid affects myogenic constriction in response to intraluminal pressure elevation (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22285599
Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22374260
Sex differences in cannabinoid receptor-1 (CB1) pharmacology in mice selectively bred for high voluntary wheel-running behavior (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22405775
WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22634229
Analgesic effects of cannabinoids on central pain syndrome (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22359935
Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22609797
Nutritional n-3 polyunsaturated fatty acids deficiency alters cannabinoid receptor signaling pathway in the brain and associated anxiety-like behavior in mice (abst – 2012) http://www.springerlink.com/content/ur5784gm34782505/
Effect of ion pairing on in vitro transcorneal permeability of a Δ(9) -tetrahydrocannabinol prodrug: potential in glaucoma therapy (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/21989812
Cannabinoid type 1 receptor ligands WIN 55,212-2 and AM 251 alter anxiety-like behaviors of marmoset monkeys in an open-field test (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/23183218
Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22697514?dopt=Abstract
WIN55,212-2 protects oligodendrocyte precursor cells in stroke penumbra following permanent focal cerebral ischemia in rats (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/23202804
Inverse relationship of cannabimimetic (R+)WIN 55, 212 on behavior and seizure threshold during the juvenile period (abst–2012) http://www.ncbi.nlm.nih.gov/pubmed/22019959
A CB₁/CB₂ receptor agonist, WIN 55,212-2, exerts its therapeutic effect in a viral autoimmune model of multiple sclerosis by restoring self-tolerance to myelin (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22561283
Novel Insights Into CB1 Cannabinoid Receptor Signaling: A Key Interaction Identified Between EC3-Loop and TMH2 (full–2013)http://jpet.aspetjournals.org/content/early/2013/02/21/jpet.112.201046.long
Effect of Cannabinoid Receptor Activation on Spreading Depression (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586901/
Striatal CB1 and D2 receptors regulate expression of each other, crip1a and delta opioid systems (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3697910/
Functional activity of the cannabinoid 1 receptor is not affected by opioid antagonists in the rat brain (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3611077/
Antibodies to cannabinoid type 1 receptor co-react with stomatin-like protein 2 in mouse brain mitochondria (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902808/
A biophysical model of endocannabinoid-mediated short term depression in hippocampal inhibition (full–2013) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0058926
Inhibition of p38/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitis (full–2013) http://www.nature.com/labinvest/journal/v93/n3/full/labinvest2012177a.html
Interactions between mu opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration (full – 2013) http://jpet.aspetjournals.org/content/early/2013/03/27/jpet.113.204099.long
Role of endogenous cannabinoid system in the gut (full – 2013) http://www.actaps.com.cn/qikan/manage/wenzhang/2013-4-12.pdf
Effects of glucagon-like peptide-1 receptor stimulation and blockade on food consumption and body weight in rats treated with a cannabinoid CB1 receptor agonist WIN 55,212-2 (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638658/
CB2 Receptor Agonists Protect Human Dopaminergic Neurons against Damage from HIV-1 gp120 (full–2013) http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0077577
Combined antiproliferative effects of the aminoalkylindole WIN55,212-2 and radiation in breast cancer cells (full–2013) http://jpet.aspetjournals.org/content/early/2013/11/20/jpet.113.205120.long
Diuretic effects of cannabinoids (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533417/
A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3677091/
Cannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682147/
Novelty-Induced Emotional Arousal Modulates Cannabinoid Effects on Recognition Memory and Adrenocortical Activity (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656371/
Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835353/
Rapid Glucocorticoid-Induced Activation of TRP and CB1 Receptors Causes Biphasic Modulation of Glutamate Release in Gastric-Related Hypothalamic Preautonomic Neurons (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560102/
Cannabinoid receptor activation in the nucleus tractus solitaries produces baroreflex-like responses in the rat (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614708/
Transdermal delivery of cannabidiol Patent 8435556 (full – 2013) https://www.google.com/patents/US8435556
Critical appraisal of the potential use of cannabinoids in cancer management (link to PDF – 2013) http://www.dovepress.com/critical-appraisal-of-the-potential-use-of-cannabinoids-in-cancer-mana-a14216
Suppression of vascular endothelial growth factor expression by cannabinoids in a canine osteosarcoma cell line (link to PDF – 2013) http://www.dovepress.com/suppression-of-vascular-endothelial-growth-factor-expression-by-cannab-a13597
Interactions between mu opioid receptor agonists and cannabinoid receptor agonists CP55940 and WIN55212-2 in rhesus monkeys: evaluation of treatment- and abuse-related effects (abst–2013) http://www.fasebj.org/cgi/content/meeting_abstract/27/1_MeetingAbstracts/1097.3?sid=7a3e6978-9a8c-4319-bca1-9f80fed2445f
WIN55, 212-2 promotes differentiation of oligodendrocyte precursor cells and improve remyelination through regulation of the phosphorylation level of the ERK 1/2 via cannabinoid receptor 1 after stroke-induced demyelination (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23148948
Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats (abst – 2013) http://link.springer.com/article/10.1007/s00213-012-2839-1
Cannabinoids and traumatic stress modulation of contextual fear extinction and GR expression in the amygdala-hippocampal-prefrontal circuit (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23433741
Characterisation of cannabinoid-induced relief of neuropathic pain in a rat model of cisplatin-induced neuropathy (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23454533
Neuroprotective effects of topical CB1 agonist WIN 55212-2 on Retinal ganglion cells after acute rise in intraocular pressure induced ischemia in rat (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23454099
Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23518609
Role of intra-accumbal cannabinoid CB1 receptors in the potentiation, acquisition and expression of morphine-induced conditioned place preference (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23523958
The non-selective cannabinoid receptor agonist WIN 55,212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer pain (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23673278
Cannabinoid 1 receptor as therapeutic target in preventing chronic epilepsy (abst–2013) http://www.fasebj.org/cgi/content/meeting_abstract/27/1_MeetingAbstracts/660.2?sid=eea722c0-971c-4daa-8b8c-38c0c63c19ad
Effect of Cannabinoids and MethoxyPolyethylene Glycols on Aqueous Humor Outflow and Vascular Tone (abst–2013) http://www.fasebj.org/cgi/content/meeting_abstract/27/1_MeetingAbstracts/lb541?sid=eea722c0-971c-4daa-8b8c-38c0c63c19ad
Effects of anandamide and other CB1 ligands on cognitive function (abst–2013) http://www.fasebj.org/cgi/content/meeting_abstract/27/1_MeetingAbstracts/1097.10?sid=eea722c0-971c-4daa-8b8c-38c0c63c19ad
Effects of compounds that interfere with the endocannabinoid system on behaviors predictive of anxiolytic and panicolytic activity in the elevated T-maze (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23711591
Dysregulation of Cannabinoid CB1 Receptor and Associated Signaling Networks in Brains of Cocaine Addicts and Cocaine-Treated Rodents (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23727505
Cannabinoid Receptor Agonist as an Alternative Drug in 5-Fluorouracil-resistant Gastric Cancer Cells (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23749906
Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptors activation in mice (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23791616
Regulation of cell proliferation by GPR55/cannabinoid receptors using (R,R’)-4’-methoxy-1-naphthylfenoterol in rat C6 glioma cell line (abst – 2013) http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=695437a2-7613-4bef-8697-2294df2da859&cKey=18ba6eb0-2c5f-4004-a56f-2d1f450e2ed1&mKey=9b2d28e7-24a0-466f-a3c9-07c21f6e9bc9
CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23860329
Activation of spinal cannabinoid cb2 receptors inhibits neuropathic pain in streptozotocin-induced diabetic mice (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23892011
Exogenous Delta9-Tetrahydrocannabinol Influences Circulating Endogenous Cannabinoids in Humans (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23899642
Prospects for cannabinoid therapies in viral encephalitis (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24021420
The Cannabinoid WIN 55,212-2 Decreases Specificity Protein (Sp) Transcription Factors and the Oncogenic Cap Protein eIF4E in Colon Cancer Cells (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24030632
Continuous central infusion of cannabinoid receptor agonist WIN 55,212-2 decreases maternal care in lactating rats: Consequences for fear conditioning in adulthood males (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24060654
PPARγ mediates the effects of WIN55,212-2, an synthetic cannabinoid, on the proliferation and apoptosis of the BEL-7402 hepatocarcinoma cells (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24062073
Moving around the molecule: Relationship between chemical structure and in vivo activity of synthetic cannabinoids (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24071522
Calcium regulation by temperature-sensitive transient receptor potential channels in human uveal melanoma cells (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24084605
Diuretic effects of cannabinoid agonists in mice (abst – 2013) http://www.sciencedirect.com/science/article/pii/S0014299913007176
Peripheral and Spinal Activation of Cannabinoid Receptors by Joint Mobilization Alleviates Postoperative Pain in Mice (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24120553
Differential effects of the cannabinoid agonist WIN55,212-2 on delay and trace eyeblink conditioning (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24128358
Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB1 and CB2 receptors (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24148808
Cannabinoid Receptor Activation Prevents the Effects of Chronic Mild Stress on Emotional Learning and LTP in a Rat Model of Depression (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24141570
Effects of WIN 55,212-2 mesylate on the anticonvulsant action of lamotrigine, oxcarbazepine, pregabalin and topiramate against maximal electroshock-induced seizures in mice (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24161913
Antineoplastic Effect of WIN 55,212-2, a Cannabinoid Agonist, in a Murine Xenograft Model of Gastric Cancer (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24335109
Improved Cardiac and Neurologic Outcomes With Postresuscitation Infusion of Cannabinoid Receptor Agonist WIN55, 212-2 Depend on Hypothermia in a Rat Model of Cardiac Arrest (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24346544
Similar anxiolytic effects of agonists targeting serotonin 5-HT1A or cannabinoid CB receptors on zebrafish behavior in novel environments (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24411165
Concurrent pharmacological modification of cannabinoid-1 and glucagon-like peptide-1 receptor activity affects feeding behavior and body weight in rats fed a free-choice, high-carbohydrate diet (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24370558
Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine inflammatory pain model (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24384256
The Cannabinoid WIN 55,212-2 Decreases Specificity Protein Transcription Factors and the Oncogenic Cap Protein eIF4E in Colon Cancer Cells (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24030632
Marijuana’s Memory Paradox (news/forum repost–2013) http://ehealthforum.com/health/interesting-t164409.html
Effects of WIN 55,212-2 (a non-selective cannabinoid CB1 and CB 2 receptor agonist) on the protective action of various classical antiepileptic drugs in the mouse 6 Hz psychomotor seizure model (full–2014) http://download.springer.com/static/pdf/828/art%253A10.1007%252Fs00702-014-1173-7.pdf?auth66=1393191519_d7b51017bd9f9b481c18158f0312786b&ext=.pdf
The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells (full – 2014) http://www.jbc.org/content/early/2014/03/18/jbc.M113.536953.long
Involvement of the Cannabinoid CB1 Receptor in Modulation of Dopamine Output in the Prefrontal Cortex Associated with Food Restriction in Rats (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3954872/
Chronic ethanol alters network activity and endocannabinoid signaling in the prefrontal cortex (full–2014) http://journal.frontiersin.org/Journal/10.3389/fnint.2014.00058/full
Involvement of PAR-4 in Cannabinoid-Dependent Sensitization of Osteosarcoma Cells to TRAIL-Induced Apoptosis (full–2014) http://www.ijbs.com/v10p0466.htm
Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery (full–2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998744/
Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders (full – 2014) http://onlinelibrary.wiley.com/doi/10.1111/epi.12631/full
Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain (full – 2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915876/
Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24412835
Effects of cannabinoid and vanilloid drugs on positive and negative-like symptoms on an animal model of schizophrenia: The SHR strain (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24556469
WIN induces apoptotic cell death in human colon cancer cells through a block of autophagic flux dependent on PPARγ down-regulation (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24696378
The CB1 Receptor as an Important Mediator of Hedonic Reward Processing (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24718372
Cannabinoids negatively modulate striatal glutamate and dopamine release and behavioural output of acute d-amphetamine (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24867330
WIN55212-2 impairs non-associative, recognition and spatial memory in rats via CB1 receptor stimulation (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24867078
Terpenes and Lipids of the Endocannabinoid and Transient Receptor Potential-channel Biosignaling Systems (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24866555
Cannabinoids Prevent the Effects of a Footshock Followed by Situational Reminders on Emotional Processing (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24897957
Analgesic tolerance and cross-tolerance to the cannabinoid receptors ligands hemopressin, VD-hemopressin(α) and WIN55,212-2 at the supraspinal level in mice (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25010019
Involvement of β-arrestin-2 and Clathrin in Agonist-Mediated Internalization of the Human Cannabinoid CB2 Receptor (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25023974
Differential Activation of Intracellular vs Plasmalemmal CB2 Cannabinoid Receptors (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25033246
Effects of opioids and cannabinoids during chronic morphine treatment in rhesus monkeys (abst–2014) http://www.fasebj.org/content/28/1_Supplement/658.3.abstract?sid=467bb529-0ecc-4ddc-af27-3f56f520a102
Combined antiproliferative effects of the aminoalkylindole WIN55,212-2 and radiation in breast cancer cells (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24259678
The therapeutic efficacy of cannabinoid receptor type 1 ligands in Huntington’s disease may depend on their functional selectivity (abst – 2014) http://www.fasebj.org/content/28/1_Supplement/846.6.abstract?sid=467bb529-0ecc-4ddc-af27-3f56f520a102
The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24644287
Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington’s disease (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25123645
The interaction between serotonergic and cannabinoidergic modulations involved in the fear extinction (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25069241


WWL-70
Selective inhibition of alpha/beta-hydrolase domain 6 attenuates neurodegeneration, alleviates blood brain barrier breakdown, and improves functional recovery in a mouse model of traumatic brain injury (full–2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636589/
Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6 (full–2013) http://www.pnas.org/content/110/43/17558.long


XLR-11
Acute Kidney Injury Associated with Synthetic Cannabinoid Use — Multiple States, 2012 (report–2013) http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6206a1.htm
First Metabolic Profile of XLR-11, a Novel Synthetic Cannabinoid, Obtained by Using Human Hepatocytes and High-Resolution Mass Spectrometry (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24014837
Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles (abst–2013)http://www.ncbi.nlm.nih.gov/pubmed/23916483
Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography-tandem mass spectrometry (abst–2013) http://www.ncbi.nlm.nih.gov/pubmed/24418231
Identification and quantification of synthetic cannabinoids in ‘spice-like’ herbal mixtures: A snapshot of the German situation in the autumn of 2012 (full–2014) http://onlinelibrary.wiley.com/doi/10.1002/dta.1499/full
Quantitative Measurement of XLR11 and UR-144 in Oral Fluid by LC-MS-MS (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24812645
Enzyme-Linked Immunosorbent Assay (ELISA) for the Detection of Use of the Synthetic Cannabinoid Agonists UR-144 and XLR-11 in Human Urine (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/24908262
Acute kidney injury associated with smoking synthetic cannabinoid (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25089722
Driving Under the Influence of Synthetic Cannabinoid Receptor Agonist XLR-11 (abst–2014) http://www.ncbi.nlm.nih.gov/pubmed/25088081


Advertisements